Likely The Most Overlooked Substitute For The Tamoxifen

Six studies (2494 subjects) evaluated RFS (Burnett et?al, 2011, 2012; Amadori et?al, 2012; Brunnberg et?al, 2012; Castaigne et?al, 2012; Petersdorf et?al, 2013). GO resulted in a significant improvement in RFS. Pooled HR for RFS was 0��84 (95%CI 0��71�C0��99; P?=?0��04; Fig?2B). Overall heterogeneity was high (I2?=?56%). Pooled HR from subjects with low/intermediate-risk AML showed statistically significant improvement in RFS with GO [HR?=?0��78 (95%CI 0��63�C0��96); P?=?0��02]. Pooled HR for subjects with high-risk AML was 0��96 (95%CI 0��78�C1��17; P?=?0��67; Fig S2). There was low heterogeneity within the subgroup of subjects with low/intermediate-risk AML (I2?= 25%) and among subjects with high-risk AML (I2?=?0%). Test of interaction between subgroups was non-significant (P?=?0��16). Three studies (647 subjects) reported EFS (Delaunay et?al, 2011; Brunnberg et?al, 2012; Castaigne et?al, 2012). The http://www.selleckchem.com/products/Fludarabine(Fludara).html addition of GO improved EFS. Pooled HR for EFS was 0��59 (95%CI 0��48�C0��74; P? https://en.wikipedia.org/wiki/Chlormezanone with high-risk AML was 1��03 (95%CI 0��50�C2��13; P?=?0��94; Fig S3). Test of interaction between subgroups was non-significant (P?=?0��11). Data on CR were available from six studies (3470 subjects; Burnett et?al, 2011, 2012; Delaunay http://www.selleckchem.com/products/Nolvadex.html et?al, 2011; Brunnberg et?al, 2012; Castaigne et?al, 2012; Petersdorf et?al, 2013). GO addition resulted in no difference in CR. Pooled RR for CR was 0��95 (95%CI 0��86�C1��05; P?=?0��72; Fig S4). Overall heterogeneity was low (I2?=?0%). Data on CR+CRi/CRp was available from six studies (3688 subjects; Burnett et?al, 2011, 2012; Amadori et?al, 2012; Brunnberg et?al, 2012; Castaigne et?al, 2012; Petersdorf et?al, 2013). Adding GO did not result in better CR+CRi/CRp. Pooled RR was 1��00 (95%CI 0��90�C1��10; P?=?0��97; Fig S5). Overall heterogeneity was low (I2?=?0%). Data from six RCTs (3461 subjects) was extractable for early death (defined as induction death or 30-d mortality; Burnett et?al, 2011, 2012; Delaunay et?al, 2011; Brunnberg et?al, 2012; Castaigne et?al, 2012; Petersdorf et?al, 2013). Addition of GO was associated with a significant increase in early death [RR?=?1��60 (95%CI 1��07�C2��39); P?=?0��02; Fig?3]. Overall heterogeneity was high (I2?=?51%). Data on hepatic VOD/SOS was available from three studies (647 subjects; Delaunay et?al, 2011; Brunnberg et?al, 2012; Castaigne et?al, 2012). GO was associated with increased risk of hepatic VOD/SOS with a pooled RR of 7��67 (95%CI 1��41�C41��74; P?=?0��02; Fig S6). Overall heterogeneity was low (I2?=?0%).